{
  "paper": {
    "title": "SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade",
    "doi": "10.1038/s41586-025-09006-8",
    "publication_year": 2025,
    "domain": "oncology-immunology",
    "study_type": "preclinical+retrospective"
  },
  "core_question": "Does intratumoral SARS-CoV-2 mRNA vaccination prime tumors to respond more effectively to anti-PD-L1 checkpoint blockade?",
  "datasets_or_cohorts": [
    {
      "id": "mouse-combo",
      "label": "Mouse combination therapy cohort",
      "sample_size_or_observations": "78 tumor-bearing mice pooled across repeat experiments",
      "description": "Preclinical cohort testing intratumoral mRNA vaccine plus anti-PD-L1 therapy for tumor control in multiple murine models."
    },
    {
      "id": "mouse-control",
      "label": "Mouse matched control cohorts",
      "sample_size_or_observations": "84 tumor-bearing mice across vaccine-only, ICI-only, and vehicle groups",
      "description": "Matched control tumors evaluating vaccine-only, ICI-only, and vehicle treatments without combined therapy."
    },
    {
      "id": "human-retrospective",
      "label": "Retrospective metastatic patient cohort",
      "sample_size_or_observations": "130 metastatic patients total",
      "description": "Retrospective analysis comparing ICI outcomes by prior SARS-CoV-2 mRNA vaccination status among metastatic patients."
    }
  ],
  "major_limitations": [
    "The human analysis is retrospective, non-randomized, and likely confounded.",
    "Vaccination timing relative to ICI initiation varied across patients.",
    "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.",
    "Mouse model effects may not map one-to-one to all human tumors."
  ]
}
